Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00536601 · ClinicalTrials.gov registry record · NA
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
A NA study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 174
- Enrollment target
NCT00536601 is a NA study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 174 participants.
The verdict
NCT00536601, a NA study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 174 participants
- Enrollment target
Study Summary
This pilot trial studies different high-dose chemotherapy regimens with or without total-body irradiation (TBI) to compare how well they work when given before autologous stem cell transplant (ASCT) in treating patients with hematologic cancer or solid tumors. Giving high-dose chemotherapy with or without TBI before ASCT stops the growth of cancer cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood or bone marrow and stored. More chemotherapy may be given to prepare for the stem cell transplant. The stem cells are then returned to the patient to replace the blood forming cells that were destroyed by the chemotherapy.
Interventions
- DRUG cyclophosphamide
- DRUG etoposide
- DRUG melphalan
- DRUG carmustine
- DRUG busulfan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2006-06-29 |
| Est. Completion | 2018-07-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00536601
The ClinicalTrials.gov registry entry for NCT00536601 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00536601 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00536601 about?
NCT00536601 is a clinical study titled "High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors". This pilot trial studies different high-dose chemotherapy regimens with or without total-body irradiation (TBI) to compare how well they work when given before autologous stem cell transplant (ASCT) in treating patients with hematologic cancer or solid tumors. Giving high-dose chemotherapy with or w...
What is the current status of trial NCT00536601?
This trial is currently completed. It is a NA study. The enrollment target is 174 participants. The study started on 2006-06-29. Estimated completion is 2018-07-09.
What interventions are being tested in trial NCT00536601?
The interventions under investigation include: cyclophosphamide (DRUG), etoposide (DRUG), melphalan (DRUG), carmustine (DRUG), busulfan (DRUG).
Who is sponsoring clinical trial NCT00536601?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.